CIK 0001559053 · Accelerated filer
PROTHENA CORP PUBLIC LTD CO
Sign in to watch- Ticker
- PRTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Ireland
- Entity type
- operating
- Phone
- 011-353-1-236-2500
- Business address
- 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, GRAND CANAL DOCKLANDS, DUBLIN 2, Ireland, D02 VK60
- Former names
- Prothena Corp plc, Neotope Corp Ltd
- Open-market buys, last 90 days
- $9,848,721
- in 10 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,848,721. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-28 | Kinney Gene G. President and CEO | Option exercise · Restricted Stock Units | −84,000 | 0 | ||
| 2026-07-28 | Kingston Anne Evans Chief Strategy Officer | Shares withheld for taxes 10b5-1 | −3,498 | $8.56 | $30K | 63,444 |
| 2026-07-28 | Isaacs Michael John General Counsel & Company Sec. | Shares withheld for taxes 10b5-1 | −4,694 | $8.56 | $40K | 44,131 |
| 2026-06-16 | SCULLY WILLIAM P 10% owner | Purchase | +20,000 | $7.90 | $158K | 756,000 |
| 2026-06-15 | SCULLY WILLIAM P 10% owner | Gift | −325,000 | 736,000 | ||
| 2026-06-11 | SCULLY WILLIAM P 10% owner | Purchase | +125,000 | $8.17 | $1.0M | 1,061,000 |
| 2026-06-04 | SCULLY WILLIAM P 10% owner | Purchase | +50,000 | $9.31 | $465K | 936,000 |
| 2026-06-02 | SCULLY WILLIAM P 10% owner | Purchase | +50,000 | $9.43 | $471K | 886,000 |
| 2026-05-22 | SCULLY WILLIAM P 10% owner | Purchase | +100,000 | $9.81 | $981K | 836,000 |
| 2026-05-15 | WELCH DANIEL G Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-05-15 | Selkoe Dennis J. Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-05-15 | Ekman Lars Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-05-15 | Dunn William H. Jr. Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-05-15 | Cooke Shane Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-05-15 | COLLIER RICHARD T Director | Grant or award · Stock Option (Right to Buy) | +27,000 | 27,000 | ||
| 2026-04-10 | Kingston Anne Evans Chief Strategy Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-03-03 | Zago Wagner M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2026-03-03 | Walker Karin L Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2026-03-03 | Swanson Chad J. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2026-03-03 | Smith Brandon S. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 |
Page 3 of 9 · 172 trades